Cochrane · systematic review · CD013281
Interventions for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries
Mishu, MP, Uphoff, E, Aslam, F, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
15
No studies
3
Included studies
NR
No studies 3 · 16.7%Ungraded 0 · 0%Very low 3 · 16.7%Low 3 · 16.7%Moderate 7 · 38.9%High 2 · 11.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Atypical compared with typical antipsychotic medications for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries
Population: Adults with mental disorders in low‐ and middle‐income countries
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diabetes (ADA criteria) (6 weeks) Atypical vs typical antipsychotic medications | RR 0.5 [0.03, 7.73] | 1 study · 93 participants | Low Downgraded: imprecision |
Drop‐outs (6 to 54 weeks) Atypical vs typical antipsychotic medications | RR 1.31 [0.63, 2.69] | 2 studies · 144 participants | Low Downgraded: risk of bias, imprecision |
Fasting blood glucose (6 to 8 weeks) Atypical vs typical antipsychotic medications | no estimate extracted | 2 studies · 211 participants | Moderate Downgraded: risk of bias |
BMI (8 to 54 weeks) Atypical vs typical antipsychotic medications | no estimate extracted | 2 studies · 141 participants | Moderate Downgraded: risk of bias |
Metformin compared with placebo for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries
Population: Adults with mental disorders in low‐ and middle‐income countries
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diabetes Metformin vs placebo | no estimate extracted | NR | No studies |
Drop‐outs (12 to 14 weeks) Metformin vs placebo | RR 1.22 [0.09, 16.35] | 3 studies · 158 participants | Moderate Downgraded: risk of bias, imprecision |
Fasting blood glucose (12 to 14 weeks)(endpoint data) Metformin vs placebo | no estimate extracted | 3 studies · 173 participants | Moderate Downgraded: imprecision |
Fasting blood glucose (12 to 14 weeks)(change from baseline data) Metformin vs placebo | no estimate extracted | 2 studies · 91 participants | High |
BMI (12 to 14 weeks) Metformin vs placebo | no estimate extracted | 5 studies · 264 participants | High |
Melatonin compared with placebo for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries
Population: Adults with mental disorders in low‐ and middle‐income countries
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diabetes Melatonin vs placebo | no estimate extracted | NR | No studies |
Drop‐outs (8 weeks) Melatonin vs placebo | RR 1 [0.38, 2.66] | 1 study · 48 participants | Low Downgraded: imprecision |
Fasting blood glucose (8 to 12 weeks) (endpoint data) Melatonin vs placebo | no estimate extracted | 2 studies · 102 participants | Moderate Downgraded: risk of bias |
Fasting blood glucose (8 to 12 weeks) (change from baseline data) Melatonin vs placebo | no estimate extracted | 1 study · 100 participants | Moderate Downgraded: risk of bias, imprecision |
BMI (8 to 12 weeks) Melatonin vs placebo | no estimate extracted | 3 studies · 202 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
SSRI antidepressants compared with TCA for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries
Population: Adults with mental disorders in low‐ and middle‐income countries
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diabetes SSRI antidepressants vs TCA | no estimate extracted | NR | No studies |
Drop‐outs (12 weeks) SSRI antidepressants vs TCA | RR 0.34 [0.11, 1.01] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Fasting blood glucose (8 to 12 weeks) SSRI antidepressants vs TCA | no estimate extracted | 3 studies · 141 participants | Moderate Downgraded: risk of bias |
BMI (12 weeks) SSRI antidepressants vs TCA | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision |